We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

XELB:NASDAQXcel Brands, Inc Analysis

Data as of 2026-08-01 - not real-time

$1.20

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Xcel Brands (XELB) is trading at $1.20, just above its computed support of $1.14 and well below the 52‑week high of $2.66, indicating limited upside room. The 20‑day SMA ($1.389) sits above the current price, while the 50‑day SMA ($1.756) is markedly higher, reflecting a bearish medium‑term price bias. However, the RSI of 33 suggests the stock is oversold, and the MACD shows a marginal bullish crossover (histogram +0.0003), hinting at a possible short‑term rebound. Volatility is extreme at ~74 % over the past 30 days and beta exceeds 1.7, underscoring a highly volatile and market‑sensitive profile.
Fundamentally, the company is in distress: trailing EPS is –$4.32, operating margin is –159 %, and cash flow is deeply negative with $7.9 M free‑cash‑flow deficit. Debt totals $17.5 M against a modest cash balance of $0.18 M, yielding a debt‑to‑equity ratio over 130 %. The price‑to‑book of 0.46 suggests a discount to net assets, but the lack of earnings and a negative ROE (‑89 %) raise serious concerns. No dividend is paid, and the forward PE is negative. The recent licensing agreement with KBL Group for the OFF/DUTY brand could provide a modest revenue boost, but its impact is uncertain given the company's overall financial weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Oversold RSI and marginal bullish MACD signal
  • Price near technical support
  • Decreasing volume and high short‑term volatility

Medium Term

1–3 years
Cautious
Model confidence: 6/10

Key Factors

  • Sustained negative earnings and operating margins
  • Heavy debt load relative to cash
  • Elevated beta and 30‑day volatility

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Structural cash‑flow deficits and poor ROE
  • Absence of dividend and limited growth prospects
  • Uncertain upside from licensing agreement amid high financial risk

Key Metrics & Analysis

Financial Health

Revenue Growth-14.10%
P/E Ratio-0.6
ROE-88.78%
ROA-10.11%
Debt/Equity133.12
P/B Ratio0.5
Op. Cash Flow$-6466000
Free Cash Flow$-7929000

Technical Analysis

TrendNeutral
RSI33.1
Support$1.14
Resistance$1.98
MA 20$1.39
MA 50$1.76
MA 200$1.57
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88

Valuation

Target Price$5.00
Upside/Downside316.67%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.72
Volatility73.77%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.